10x Genomics (TXG)

• Market cap: $1.6B
• 1 day: -2.06%
• 5 days: 3.79%
• 1 month: -4.46%
• 3 months: 21.78%
• 6 months: 19.52%
• Year to date: -9.37%
• 1 year: -39.93%
• 5 years: -89.3%
• 10 years: -75.62%
• Sector: Healthcare
• Industry: Health Information Services

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Employees: 1,306

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

71% more call options, than puts

Call options by funds: $4.44M | Put options by funds: $2.6M

56% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 72

55% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 49

43% more capital invested

Capital invested by funds: $993M [Q1] → $1.42B (+$426M) [Q2]

10% more funds holding

Funds holding: 269 [Q1] → 295 (+26) [Q2]

5.15% more ownership

Funds ownership: 105.14% [Q1] → 110.29% (+5.15%) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13
• Avg. target: $14.6
• High target: $17

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Piper Sandler David Westenberg	$15	Neutral Initiated	11 Sep 2025
Morgan Stanley Tejas Savant	$17	Overweight Maintained	12 Aug 2025
UBS Dan Leonard	$13	Neutral Maintained	8 Aug 2025
Barclays Luke Sergott	$15	Overweight Maintained	8 Aug 2025
B of A Securities Derik De Bruin	$13	Neutral Maintained	26 Jun 2025